This article was originally published in The Tan Sheet
Congress "strongly urges" President Bush to approach Canadian government to immediately "stem the widespread and increasing availability in Canada and the illegal importation into the U.S. of pseudoephedrine," according to House bill introduced Feb. 14. HR 3782, introduced by Rep. Doug Ose (R-Calif.) and 22 co-sponsors notes Canada lacks legislative framework to counter the drug's trafficking. Legislation, which addresses illegal production, distribution, use of meth, was referred to the Commerce, Agriculture, Education, Judiciary committees. Similar concurrent resolution was introduced in House Feb. 6 (1"The Tan Sheet" Feb. 11, 2002, In Brief)...
You may also be interested in...
Legislation limiting retail sales of pseudoephedrine-containing OTCs to 9 g per purchase introduced July 19 by Sens. Dianne Feinstein (D-Calif.), Tim Hutchinson (R-Ark.) and Herb Kohl (D-Wisc.). Provision "to close the 'blister pack loophole' would make it harder for methamphetamine manufacturers to obtain large quantities" of precursor ephedrine, Hutchinson says in same-day 1press release announcing bill. S 2763 "will still allow consumers to purchase weeks or months worth of cold medicine at once, but will prevent large-scale purchases by meth dealers," Feinstein adds. Bill would provide $125.5 mil. to fund cleanup of meth labs, train law enforcement agents to prosecute meth offenses. Rep. Doug Ose (R-Calif.) has introduced similar legislation in the House (2"The Tan Sheet" Feb. 25, 2002, In Brief)...
Concurrent Resolution 317, "expressing the sense of the Congress that the President should open a dialogue with...Canada to discuss the smuggling from Canada into the [U.S.] of large quantities of pseudoephedrine, a necessary ingredient in the production of methamphetamines," introduced in House Feb. 6 by George Radanovich (R-Calif.) and four co-sponsors. Fifty-four people were arrested Jan. 10 as part of an investigation into illegal pseudoephedrine trafficking (1"The Tan Sheet" Jan. 14, 2002, In Brief)...
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Sign in to continue reading.
Need a specific report?
1000+ reports available
New to Pink Sheet?
Start a free trial today!
Register for our free email digests: